Published June 17, 2021
| Version v1
Patent
Open
MICROBIOME BIOMARKERS IMMUNOTHERAPY RESPONSIVENESS: DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES THEREOF
Creators
- 1. University of Chicago
Contributors
Patent applicant:
Description
Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.
Files
US20210177918.pdf
Files
(4.0 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:76248d4e819d014d900d4dc384ea018a
|
4.0 MB | Preview Download |
Additional details
Identifiers
- Patent application number
- US 201816618700 A
- Patent number
- US 2021/0177918 A1
- Other
- oai:uchicago.tind.io:8091
Dates
- Patent filed
-
2018-06-05